Mohali plant supply constraints persist
Supplies from Mohali plant are not normal; issues with product prioritization and quality clearances are causing delays.
high · management_commentary
Sunpharma Ltd — Q3 FY24
Sun Pharma reported Q3 FY24 consolidated revenue of INR 12,157 crore, up 9.5% YoY, driven by strong specialty sales (up 26.1% to $296M) and India formulation growth of 11.4%.
bullish
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
CEQUA facing increased competition in dry eye space
CEQUA's market share has declined due to generic Restasis and new entrants with different mechanisms of action.
medium · analyst_questionRed Sea supply chain disruption risk
Management is monitoring the Red Sea situation; potential for shipment delays if situation does not normalize.
medium · analyst_questionTaro merger may not receive minority approval
The $43/share offer requires approval from Taro's minority shareholders; failure could derail the merger.
high · management_commentary